898800-26-5

898800-26-5 structure

Name: AZ876
Chemical Name: AZ876
CAS Number: 898800-26-5
Molecular Formula: C₂₄H₂₉N₃O₃S
Molecular Weight: 439.570
Catalog: Signaling Pathways Metabolic Enzyme/Protease LXR
Create Date: 2018-04-19 00:09:21
Modify Date: 2024-01-02 17:45:44
AZ876 is a novel high-affinity LXR agonist. AZ876 was 25-fold and 2.5-fold more potent than GW3965 (HY-10627) on human (h)LXRα and hLXRβ respectively.(1) AZ876 suppressed up-regulation of hypertrophy- and fibrosis-related genes, and further inhibited prohypertrophic and profibrotic transforming growth factor β (TGFβ)-Smad2/3 signalling.(2) AZ876 prevented TGFβ- and angiotensin II-induced fibroblast collagen synthesis, and inhibited up-regulation of the myofibroblastic marker, α-smooth muscle actin.(3) The reference for administration is 20 umol/kg/day in vivo.

Name	AZ876
Synonyms	MFCD30377191 AZ12260493 2-(2-Methyl-2-propanyl)-5-phenyl-4-{[4-(1-piperidinyl)phenyl]amino}-1,2-thiazol-3(2H)-one 1,1-dioxide 3(2H)-Isothiazolone, 2-(1,1-dimethylethyl)-5-phenyl-4-[[4-(1-piperidinyl)phenyl]amino]-, 1,1-dioxide

Description	AZ876 is a novel high-affinity LXR agonist. AZ876 was 25-fold and 2.5-fold more potent than GW3965 (HY-10627) on human (h)LXRα and hLXRβ respectively.(1) AZ876 suppressed up-regulation of hypertrophy- and fibrosis-related genes, and further inhibited prohypertrophic and profibrotic transforming growth factor β (TGFβ)-Smad2/3 signalling.(2) AZ876 prevented TGFβ- and angiotensin II-induced fibroblast collagen synthesis, and inhibited up-regulation of the myofibroblastic marker, α-smooth muscle actin.(3) The reference for administration is 20 umol/kg/day in vivo.
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> LXR Research Areas >> Cancer
References	[1]. Cannon MV et al. The liver X receptor agonist AZ876 protects against pathological cardiac hypertrophy and fibrosis without lipogenic side effects. Eur J Heart Fail. 2015 Mar;17(3):273-82. [2]. van der Hoorn J et al. Low dose of the liver X receptor agonist, AZ876, reduces atherosclerosis in APOE*3Leiden mice without affecting liver or plasma triglyceride levels. Br J Pharmacol. 2011 Apr;162(7):1553-63.